Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2025 | Characterizing TP53 Y220C mutations across solid tumors

Alison Schram • 28 Apr 2025
AACR 2025
General

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the clinical and genomic landscape of TP53 Y220C-mutated solid tumors. This hotspot mutation, present in a small proportion of tumors, alters protein conformation and is targetable by emerging small-molecule reactivators. The analysis highlights its prevalence across cancer types, especially in high-grade serous ovarian cancer, and shows genomic similarity to other TP53-mutant tumors. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alison Schram

NRG1 fusion-positive tumors and real-world insights in PDAC
8:56
NRG1 fusion-positive tumors and real-world insights in PDAC
Alison Schram • 28 Apr 2025
MYTHIC: lunresertib and camonsertib in ovarian and endometrial cancers
4:33
MYTHIC: lunresertib and camonsertib in ovarian and endometrial cancers
Alison Schram • 28 Apr 2025
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
0:46
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
Alison Schram • 21 Oct 2023
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
1:56
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals